Active, not recruitingPHASE1, PHASE2NCT06185335
A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A
Studying Hemophilia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Biocad
- Principal Investigator
- Arina V Zinkina-Orikhan, PhDDirector of Clinical Development Department, BIOCAD
- Intervention
- ANB-010, dose 1(genetic)
- Enrollment
- 50 enrolled
- Eligibility
- 18 years · MALE
- Timeline
- 2023 – 2033
Study locations (17)
- State Autonomous Institution for Healthcare "Chelyabinsk Regional Clinical Hospital", Chelyabinsk, Russia
- State budgetary healthcare institution Leningrad Regional Clinical Hospital, Gatchina, Russia
- Kuzbass Clinical Hospital named after S.V. Belyaev, Kemerovo, Russia
- Federal State Budgetary Organization of Science "Kirov Research Institute of Hematology and Blood Transfusions of Federal Medical Biological agency", Kirov, Russia
- Federal State Budgetary Institution "National Medical Research Centre for Hematology" of the Ministry of Health of Russian Federation (Department of Clinical Diagnostics for Hematology and Hemostasis Disorders), Moscow, Russia
- Federal State Budgetary Institution "National Medical Research Centre for Hematology" of the Ministry of Health of Russian Federation (Department of Traumatology and Reconstructive and Restorative Orthopedics for Patients with Hemophilia), Moscow, Russia
- Research Center for Hematology MHSD RF, Moscow, Russia
- Federal Budgetary Institution "Moscow City Clinical Hospital named after S. P. Botkin", Moscow, Russia
- LLC "Medis", Nizhny Novgorod, Russia
- State Novosibirsk Regional Clinical Hospital, Novosibirsk, Russia
- Russian Research Institute of Hematology and Transfusiology Federal State Institution of Federal Medical and Biological Agency, Saint Petersburg, Russia
- City Polyclinic №37, Saint Petersburg, Russia
- Almazov National Medical Research Centre, Saint Petersburg, Russia
- Federal State Budgetary Educational Institution of Higher Education "Samara State Medical University" of the Ministry of Healthcare of the Russian Federation, Samara, Russia
- State Institution "Komi Republican Oncological Dispensary", Syktyvkar, Russia
- +2 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06185335 on ClinicalTrials.govOther trials for Hemophilia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT07406139PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE3NCT04563520SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisEmory University
- RECRUITINGNCT07101926Monitoring of Anti-TFPI in HemophiliaHospices Civils de Lyon
- RECRUITINGPHASE4NCT06941870Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial HypertrophySanofi
- RECRUITINGNCT07314983Long-term Anticoagulation in a Patient With Severe Hemophilia AUniversity Hospital, Strasbourg, France
- RECRUITINGPHASE4NCT06940830Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog AlfaSwedish Orphan Biovitrum
- RECRUITINGPHASE1NCT06703606A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.Pfizer
- RECRUITINGPHASE3NCT06833983To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia AGritgen Therapeutics Co., Ltd.